Literature DB >> 10563647

Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis.

A Greco1, L Minghetti, G Sette, C Fieschi, G Levi.   

Abstract

The CSF level of the isoprostane 8-epi-prostaglandin (PG)-F2alpha (a reliable marker of oxidative stress in vivo) was three times higher in subjects with definite MS than in a benchmark group of subjects with other neurologic diseases. This increase was not correlated with that of PGE2 levels, measured as an index of cyclooxygenase activity, and was much lower in steroid-treated patients. The levels of 8-epi-PGF2alpha were moderately correlated with the degree of disability.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10563647     DOI： 10.1212/wnl.53.8.1876

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  18 in total

Review 1.  Antioxidants in multiple sclerosis: do they have a role in therapy?

Authors:  Noel G Carlson; John W Rose
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  Patients with multiple sclerosis show increased oxidative stress markers and somatic telomere length shortening.

Authors:  Jing-Zhi Guan; Wei-Ping Guan; Toyoki Maeda; Xie Guoqing; Wan GuangZhi; Naoki Makino
Journal:  Mol Cell Biochem       Date:  2014-11-26       Impact factor: 3.396

3.  The cyclooxygenase-2 pathway via the PGE₂ EP2 receptor contributes to oligodendrocytes apoptosis in cuprizone-induced demyelination.

Authors:  Sara Palumbo; Christopher D Toscano; Laura Parente; Roberto Weigert; Francesca Bosetti
Journal:  J Neurochem       Date:  2011-07-18       Impact factor: 5.372

Review 4.  Cyclopentenone eicosanoids as mediators of neurodegeneration: a pathogenic mechanism of oxidative stress-mediated and cyclooxygenase-mediated neurotoxicity.

Authors:  Erik S Musiek; Ginger L Milne; BethAnn McLaughlin; Jason D Morrow
Journal:  Brain Pathol       Date:  2005-04       Impact factor: 6.508

5.  Reduced creatine kinase B activity in multiple sclerosis normal appearing white matter.

Authors:  Christel Steen; Nadine Wilczak; Johannes M Hoogduin; Marcus Koch; Jacques De Keyser
Journal:  PLoS One       Date:  2010-05-25       Impact factor: 3.240

Review 6.  Electrophilic cyclopentenone isoprostanes in neurodegeneration.

Authors:  Erik S Musiek; Bethann McLaughlin; Jason D Morrow
Journal:  J Mol Neurosci       Date:  2007-09       Impact factor: 3.444

7.  Scavenging of highly reactive gamma-ketoaldehydes attenuates cognitive dysfunction associated with epileptogenesis.

Authors:  Jennifer N Pearson; Eric Warren; Li-Ping Liang; L Jackson Roberts; Manisha Patel
Journal:  Neurobiol Dis       Date:  2016-12-05       Impact factor: 5.996

8.  Current Complementary and Alternative Therapies for Multiple Sclerosis.

Authors:  Allen C. Bowling; Thomas M. Stewart
Journal:  Curr Treat Options Neurol       Date:  2003-01       Impact factor: 3.598

9.  Proresolution lipid mediators in multiple sclerosis - differential, disease severity-dependent synthesis - a clinical pilot trial.

Authors:  Harald Prüss; Berit Rosche; Aaron B Sullivan; Benedikt Brommer; Oliver Wengert; Karsten Gronert; Jan M Schwab
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240

10.  Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis.

Authors:  Ada Fiorini; Tatiana Koudriavtseva; Elona Bucaj; Raffaella Coccia; Cesira Foppoli; Alessandra Giorgi; M Eugenia Schininà; Fabio Di Domenico; Federico De Marco; Marzia Perluigi
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.